Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies

By Q. Ouyang, J. Rodon, Yan Liang, Xinhong Wu, Qun Li, Lihua Song, M. Yan, Z. Tong, Yunpeng Liu, Z. Wainberg and 18 more. 2025

Subfields: Drug Discovery, Oncology

Citations in the corpus

• TROP2 expression in head and neck squamous cell carcinoma: association with the tumor immune microenvironment and clinical outcome (2026, unknown): “…including phase II trials of Sacituzumab govitecan-based combinations (NCT07063212) and next-generation ADCs such as sacituzumab tirumotecan (NCT07088211), as well as basket studies including HNSCC expansion cohorts, supporting the feasibility of TROP2-targeted approaches in this disease (55).”